EGFR and non-small cell lung carcinoma: In the ADAURA trial, a phase 3 trial comparing osimertinib with a placebo in patients with completely resected EGFR‐mutant NSCLC, the CNS disease‐free survival was significantly longer in the Osimertinib group than that of the placebo.9